Mario E. Lacouture on the Psychosocial Impact of Dermatologic AEs
Mario E. Lacouture, MD, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
This impact has been demonstrated in questionnaires from several studies. Lacouture says he has encountered patients who are not willing to go to work because they do not want to disclose that an acneiform rash is from treatment for melanoma. Lacouture has also seen patients who have been unable to sleep because of rash or pruritus.
Finally, he says that both physicians and nurses need to focus on helping their patients live better as well as longer.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
